Compare PMCB & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMCB | ALBT |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.9M |
| IPO Year | N/A | N/A |
| Metric | PMCB | ALBT |
|---|---|---|
| Price | $0.96 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.9M | 58.2K |
| Earning Date | 12-15-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | N/A | ★ $1,611,940.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $162.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $1.21 |
| 52 Week High | $1.90 | $11.66 |
| Indicator | PMCB | ALBT |
|---|---|---|
| Relative Strength Index (RSI) | 52.21 | 30.10 |
| Support Level | $0.94 | $1.37 |
| Resistance Level | $1.51 | $1.77 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 35.97 | 5.29 |
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.